<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187002</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-41589</org_study_id>
    <nct_id>NCT03187002</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion</brief_title>
  <official_title>Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion: A Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-frequency, high-intensity transcutaneous electrical nerve-stimulation (TENS) is an&#xD;
      inexpensive and non-invasive pain control approach. TENS, pulsating electrical currents that&#xD;
      activate underlying nerves, does not have drug interactions or risk of overdose. Cochrane&#xD;
      review of TENS for acute pain found inconclusive evidence. One previous abortion trial&#xD;
      comparing TENS to IV sedation only looked at pain control in the recovery room. The&#xD;
      investigators propose a randomized controlled trial comparing TENS to IV sedation (in&#xD;
      conjunction with local anesthesia) among women presenting for first-trimester surgical&#xD;
      abortion. Primary outcome will be perceived pain by Visual Analogue Scale (VAS) during&#xD;
      aspiration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aspiration Pain</measure>
    <time_frame>Intraoperative, collected during procedure at the time of aspiration (up to 30 seconds)</time_frame>
    <description>Pain with aspiration, assessed by visual analogue scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speculum Placement Pain</measure>
    <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
    <description>Pain with speculum placement, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tenaculum Placement Pain</measure>
    <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
    <description>Pain at time of tenaculum placement, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracervical Block Pain</measure>
    <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
    <description>Pain with paracervical block, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual Cervical Dilation Pain</measure>
    <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
    <description>Pain with manual cervical dilation, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speculum Removal Pain</measure>
    <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
    <description>Pain with speculum removal, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Intraoperative, collected during procedure (up to 20 minutes)</time_frame>
    <description>Time from speculum placement to speculum removal, measured in minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Abortion in First Trimester</condition>
  <arm_group>
    <arm_group_label>Transcutaneous electrical nerve stimulation (TENS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutaneous electrical nerve stimulation (TENS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate IV Sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl, versed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.</description>
    <arm_group_label>Transcutaneous electrical nerve stimulation (TENS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moderate IV Sedation</intervention_name>
    <description>IV sedation with fentanyl and versed</description>
    <arm_group_label>Moderate IV Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SHAM: Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
    <arm_group_label>Moderate IV Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SHAM: Moderate IV Sedation</intervention_name>
    <description>Sham IV to ensure blinding</description>
    <arm_group_label>Transcutaneous electrical nerve stimulation (TENS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Presenting for surgical abortion&#xD;
&#xD;
          -  Gestational age &lt;12 weeks&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Agrees to be randomized&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Allergy to study medications (lidocaine, fentanyl, midazolam)&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Fetal demise&#xD;
&#xD;
          -  Pre-procedure use of misoprostol&#xD;
&#xD;
          -  No means of transportation following procedure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood Mar Monte</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <results_first_submitted>October 6, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03187002/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All recruitment occurred at the Planned Parenthood site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
          <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
        </group>
        <group group_id="P2">
          <title>Moderate IV Sedation</title>
          <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
          <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
        </group>
        <group group_id="B2">
          <title>Moderate IV Sedation</title>
          <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="5.5"/>
                    <measurement group_id="B2" value="28" spread="6"/>
                    <measurement group_id="B3" value="27" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <description>Measured by ultrasound on day of enrollment and procedure</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="36" upper_limit="82"/>
                    <measurement group_id="B2" value="58" lower_limit="35" upper_limit="82"/>
                    <measurement group_id="B3" value="55" lower_limit="35" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aspiration Pain</title>
        <description>Pain with aspiration, assessed by visual analogue scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
        <time_frame>Intraoperative, collected during procedure at the time of aspiration (up to 30 seconds)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Aspiration Pain</title>
          <description>Pain with aspiration, assessed by visual analogue scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="13" upper_limit="97"/>
                    <measurement group_id="O2" value="66" lower_limit="0" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Speculum Placement Pain</title>
        <description>Pain with speculum placement, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
        <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Speculum Placement Pain</title>
          <description>Pain with speculum placement, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="0" upper_limit="97"/>
                    <measurement group_id="O2" value="17.5" lower_limit="0" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tenaculum Placement Pain</title>
        <description>Pain at time of tenaculum placement, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
        <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Tenaculum Placement Pain</title>
          <description>Pain at time of tenaculum placement, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="0" upper_limit="82"/>
                    <measurement group_id="O2" value="23.5" lower_limit="0" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paracervical Block Pain</title>
        <description>Pain with paracervical block, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
        <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Paracervical Block Pain</title>
          <description>Pain with paracervical block, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" lower_limit="0" upper_limit="87"/>
                    <measurement group_id="O2" value="34.5" lower_limit="3" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Manual Cervical Dilation Pain</title>
        <description>Pain with manual cervical dilation, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
        <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Manual Cervical Dilation Pain</title>
          <description>Pain with manual cervical dilation, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="11" upper_limit="94"/>
                    <measurement group_id="O2" value="56" lower_limit="0" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Speculum Removal Pain</title>
        <description>Pain with speculum removal, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
        <time_frame>Intraoperative, collected during procedure (up to 30 seconds)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Speculum Removal Pain</title>
          <description>Pain with speculum removal, assessed by visual analog scale (VAS, 0-100mm; 0 being &quot;no pain&quot; and 100 being &quot;worst pain imaginable&quot;)</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="0" upper_limit="83"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time</title>
        <description>Time from speculum placement to speculum removal, measured in minutes</description>
        <time_frame>Intraoperative, collected during procedure (up to 20 minutes)</time_frame>
        <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
          </group>
          <group group_id="O2">
            <title>Moderate IV Sedation</title>
            <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <description>Time from speculum placement to speculum removal, measured in minutes</description>
          <population>9 participants required rescue medication (IV sedation with fentanyl and versed) during the procedure in the TENS group and were excluded from per-protocol analysis.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3.5" upper_limit="16.5"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.3" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
          <description>Transcutaneous electrical nerve stimulation (TENS)&#xD;
Transcutaneous electrical nerve stimulation (TENS): Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.&#xD;
SHAM: Moderate IV Sedation: Sham IV to ensure blinding</description>
        </group>
        <group group_id="E2">
          <title>Moderate IV Sedation</title>
          <description>Fentanyl, versed&#xD;
Moderate IV Sedation: IV sedation with fentanyl and versed&#xD;
SHAM: Transcutaneous electrical nerve stimulation (TENS): Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Manager</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507211567</phone>
      <email>fpresearch@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

